Home > Result Summaries: Compounds > zanamivir Result Summaries: zanamivir GSKStudy ID Phase Title Summary (Download) 105934 Phase 3 A post-marketing surveillance to monitor the safety of RELENZA(zanamivir) administered in Korean subjects according to the prescribing information (0 citation(s)) 106784 phase 1 Phase I, Open-label Study To Evaluate Steady-State Serum and Pulmonary Pharmacokinetics following Intravenous Administration of Zanamivir in Healthy Adult Subjects (0 citation(s)) 107485 Phase 1 An Open Label, Single-Dose, Five-Way Crossover Study Examining Relative Oral Bioavailabilty of Zanamivir With Bioenhancing Excipients Following Direct Release Into Mid-Small Intestine Using Gamma Scintigraphy and the InteliSite Companion Capsule in Healthy Subjects. (0 citation(s)) 108127 Phase 1 An Open-Label, Non-Randomized, Single-Dose Study To Evaluate Serum Zanamivir Pharmacokinetics Following Intravenous Administration to Human Subjects With Renal Impairment Compared to Subjects Without Renal Impairment (0 citation(s)) 112311 N/A Special Drug Use Investigation for Relenza (Resistant appearance) (1 citation(s)) 112312 n\a Special Drug Use Investigation for Relenza (Efficacy) (0 citation(s)) 112313 phase 4 Special Drug Use Investigation for Relenza (Pediatrics) (1 citation(s)) 112316 phase 4 Special Drug Use Investigation for Relenza® (zanamivir) (Prophylaxis) (2 citation(s)) 112321 phase 4 Special Drug Use Investigation for Relenza (Pediatrics resistance) (1 citation(s)) 113268 phase 4 Drug use investigation for Relenza (0 citation(s)) 113502 n\a Prophylactic efficacy of Relenza against influenza A and B (1 citation(s)) 113625 phase 1 A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo 10mg Administered Twice Daily for 5 Days by a Rotahaler Compared to the Diskhaler in Healthy Subjects (0 citation(s)) 113678 phase 2 An open-label, multi-center, single arm study to evaluate the safety and tolerability of intravenous zanamivir in the treatment of hospitalized adult, adolescent and pediatric subjects with confirmed influenza infection (0 citation(s)) 114045 phase 4 Collection of Patients' Background InformationRelenza® Sentinel Site Monitoring Program in Japan (3 citation(s)) 114346 phase 1 A Phase I, Randomized, Placebo-Controlled, Four-Way Crossover Study to Evaluate the Effect of Intravenous (IV) Zanamivir on Cardiac Conduction as Assessed by 12-lead Electrocardiogram (ECG) with Moxifloxacin as a Positive Control in Healthy Volunteers (0 citation(s)) 114791 n\a Assessing the safety of inhaled zanamivir exposure in pregnant women (0 citation(s)) 115008 n\a Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study (0 citation(s)) 115070 phase 1 Phase1 study of GR121167- A double blind, placebo controlled, randomized, dose ascending, single and multiple dose study to investigate the safety and pharmacokinetics following intravenous administration of GR121167 in healthy Japanese males- (0 citation(s)) 115077 phase 4 Genetic analysis of a phase IV study of inhaled zanamivir in pediatrics (1 citation(s)) 115096 phase 1 A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers (0 citation(s)) GCP/95/045 phase 1 A study to investigate the pharmacokinetics of GG167 in subjects with impaired renal function. (2 citation(s)) NAI10901 Phase 1 A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Effect of Inhaled Zanamivir 10mg od for 28 Days on Anti-Haemagglutinin Antibody Production (HAI Titre) Following Co-administration with Fluvirin™ Trivalent Influenza Vaccine in Healthy Adult Subjects (1 citation(s)) NAI10902 phase 1 An open label, randomized evaluation of the direct measurement of zanamivir concentrations in respiratory secretions following a single dose inhalation of 10mg RELENZA™ via DISKHALER in health volunteers (1 citation(s)) NAI30008 phase 3 A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Efficacy And Safety Of Inhaled Zanamivir 10mg Administered Twice Daily For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over Diagnosed With Asthma Or Chronic Obstructive Pulmo ... (1 citation(s)) NAI30009 phase 3 A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12. (1 citation(s)) NAI30010 phase 3 A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families. (1 citation(s)) NAI30012 Phase 3 A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged ? 65 Years. (1 citation(s)) NAI30015 phase 4 A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel. (1 citation(s)) NAI30020 phase 3 A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled Zanamivir (10 mg bd. via Diskhaler), for 5 days, in high risk patients with symptomatic Influenza A and / or B infection. (0 citation(s)) NAI30028 phase 3 A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic Influenza A and / or B infection. (0 citation(s)) NAI30031 Phase 3 A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households (1 citation(s)) NAI30034 phase 3 A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk … (1 citation(s)) NAI40012 phase 4 An Open-Label, Multi-center Study of the Patient Instructional Leaflet for RELENZA DISKHALER. (0 citation(s)) NAIA1009 phase 1 Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness. (1 citation(s)) NAIA3002 phase 3 A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. (2 citation(s)) NAIA3003 phase 3 A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks (1 citation(s)) NAIA3004 phase 3 A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks. (1 citation(s)) NAIA3005 phase 3 A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults. (1 citation(s)) NAIB1002 Phase 1 A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects (1 citation(s)) NAIB3001 phase 3 A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults. (1 citation(s)) NAIB3002 phase 3 A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults. (1 citation(s))
